Mayo Clinic Health System-Northwest Wisconsin Region, INC.
Mayo Clinic Health System-Northwest Wisconsin Region, INC. was paid $2.14M by Medicaid between Jan 2018 and Dec 2024, across 67 billing codes. Its largest line is 99285, emergency room visit (most serious) — 25% of everything it billed.
OSSEO, WI 54758
Next to other Critical Access Hospital providers in Wisconsin
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,797 | $163K | |
| 2019 | 10,178 | $229K | |
| 2020 | 8,097 | $247K | |
| 2021 | 10,694 | $347K | |
| 2022 | 8,394 | $305K | |
| 2023 | 9,878 | $418K | |
| 2024incomplete | 9,151 | $427K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 2,761 | 1,882 | $533K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 2,070 | 1,478 | $355K |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 519 | 450 | $321K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 951 | 808 | $263K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.7% | 8,579 | 5,997 | $187K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.2% | 5,581 | 3,900 | $68K |
| 87631 | 2.1% | 565 | 501 | $44K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.0% | 461 | 408 | $43K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 1,106 | 993 | $38K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.7% | 3,324 | 2,301 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 1,173 | 1,031 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 6,041 | 4,862 | $24K |
55 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 2,147 | $22K |
| 80053 | Comprehensive metabolic panel | 1.0% | 3,103 | $22K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 3,663 | $22K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 65 | $21K |
| 80061 | Lipid panel | <1% | 1,914 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,994 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 808 | $12K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 36 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,392 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,507 | $6K |
| 81001 | <1% | 2,086 | $4K | |
| 85610 | <1% | 3,508 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 252 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,075 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 83 | $3K |
| 86140 | <1% | 966 | $3K | |
| 83735 | <1% | 739 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 80 | $2K |
| 83605 | <1% | 222 | $942.20 | |
| 84484 | <1% | 124 | $929.20 | |
| 81025 | <1% | 142 | $896.70 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 441 | $894.34 |
| 83690 | <1% | 208 | $860.38 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,579 | $825.42 |
| 82947 | <1% | 223 | $543.60 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 56 | $542.24 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 42 | $508.45 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 140 | $451.87 |
| 80306 | <1% | 40 | $451.77 | |
| 90662 | <1% | 125 | $329.46 | |
| 99443 | <1% | 18 | $315.08 | |
| 99442 | <1% | 22 | $304.32 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 30 | $246.18 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 65 | $223.20 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 348 | $175.38 |
| 71045 | Radiologic examination, chest; single view | <1% | 59 | $159.98 |
| 80047 | <1% | 35 | $153.04 | |
| 81003 | <1% | 91 | $132.93 | |
| 90686 | <1% | 85 | $123.07 | |
| 36416 | <1% | 723 | $119.55 | |
| 83880 | <1% | 13 | $117.78 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 251 | $90.71 |
| 87103 | <1% | 14 | $89.62 | |
| 87040 | <1% | 28 | $85.66 | |
| 85379 | <1% | 14 | $82.12 | |
| 82565 | <1% | 13 | $46.60 | |
| 82948 | <1% | 23 | $36.56 | |
| 82248 | <1% | 12 | $29.40 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12 | $24.00 |
| 0764T | <1% | 19 | $16.89 | |
| 85018 | <1% | 31 | $15.78 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 171 | $15.30 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 30 | $11.01 |
| G0008 | Administration of influenza virus vaccine | 0% | 176 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.